If you’ve ever wondered whether the lipoprotein(a) test and ApoB test belong on your next lab order, you’re in the right place.

These two blood tests reveal cardiovascular risk that a standard lipid panel test can’t capture. For many people, these markers tell a story that LDL cholesterol alone never could.

Understanding what they measure, when to test, and what to do with your results can give you the knowledge to take an empowered approach to your heart health.

Her Doctor Said Nothing Could Be Done.

Sandra (name changed), a 53-year-old woman, came to me with a high Lp(a) of 108 nmol/L (indicating a higher cardiovascular disease risk). Additionally, she had LDL that had climbed from 114 to 156 mg/dL over two years. She wanted to do everything possible to prevent heart disease. Her doctor had told her there was nothing left to do nutritionally. She was already following a whole food vegan diet, and wasn’t willing to accept that answer.

She also came in with osteopenia and impaired gut health. Her gut symptoms pointed to decreased absorption, which directly affects cholesterol metabolism. A whole food vegan diet is not automatically a heart-healthy diet. Even without processed food, micro and macronutrient distribution can fall short, especially through menopause when nutrient demands shift significantly.

We built a personalized, nutrient-targeted plan within her vegan food preferences. Four months later, through dietary changes alone:

• LDL dropped from 156 to 92 mg/dL
• apoB dropped from 115 to 77mg/dL
• Non-HDL cholesterol dropped from 177 to 103 mg/dL
• Gut health normalized
• Bone health improved through targeted nutrient adequacy

We track ApoB alongside LDL because it reflects the actual number of atherogenic particles circulating in the blood, not just the cholesterol content inside them. Non-HDL cholesterol is tracked as well. It captures the cholesterol carried by all atherogenic particles combined and serves as a helpful surrogate marker when ApoB isn’t available. Together, these markers give a more comprehensive view of whether risk is truly improving. 

It’s important to note this was a trend over 4 months. We’re continuing to track her trends to reach her optimal targets. 

I share her story because if you have been told there is nothing you can do, I want you to know there’s so much you can do.

What Is the ApoB Test?

So what is the ApoB test, and why does it matter more than your standard cholesterol results? The ApoB test measures apolipoprotein B, a protein that attaches to each atherogenic lipoprotein particle in your blood, including LDL, VLDL, IDL, and Lp(a). Because each particle carries exactly one ApoB molecule, this apoB blood test gives you an accurate count of every particle capable of contributing to plaque formation in your arteries.

A standard lipid panel test measures the amount of cholesterol carried inside LDL particles, not the number of LDL particles themselves. Two people can have the same LDL cholesterol number but very different particle counts. Particle number drives cardiovascular disease risk more than cholesterol content alone. This predictive value is particularly strong in people with diabetes and metabolic syndrome. This is where standard lipid panel test results can be especially misleading.

What does the ApoB test measure exactly? It measures the total number of atherogenic lipoproteins in circulation, making it a more direct and actionable marker than total cholesterol or LDL cholesterol alone. Unlike the standard lipid panel, the ApoB lab test also doesn’t require fasting before your blood draw. This makes it a more convenient option for most people.

Optimal ApoB level: Below 80 mg/dL for most adults. For those at high cardiovascular risk, below 60-70 mg/dL is often more appropriate. 

What Is the Lipoprotein(a) Test?

The lipoprotein(a) test, also written as the Lp(a) test, measures a genetically determined lipoprotein particle that independently raises your risk for heart attack, stroke, aortic stenosis, and blood clots.

Lp(a) resembles LDL in structure but carries an additional protein that promotes plaque buildup, drives inflammation, and interferes with your body’s ability to break down blood clots. Because Lp(a) is largely determined by genetics, diet and exercise rarely move it significantly. About 70-90% of Lp(a) is genetic, but there can be changes during periods of inflammation and hormonal fluctuations such as menopause or hormonal treatments. 

Even though Lp(a) is genetically determined, knowing your number helps you address the underlying factors that make it more aggressive. These are the factors that can accelerate atherosclerosis, raise calcium scores, and contribute to vulnerable, rupture-prone plaque or silent calcification of the aortic valve.

My Personal Experience With Elevated Lipoprotein(a)

I share this from personal experience as I have elevated Lp(a) myself, along with a strong family history of heart disease. I actually found out after I had already been working in cardiology for quite some time. My family history wasn’t revealed to me until recently.

At first, I felt the same initial panic that many of my clients feel. But then I looked at my full bloodwork trends and did extensive testing. Lp(a) is a risk enhancer for me, so it’s something I continue to look into more closely, but everything else is clear at this time. That tells me to continue with my current diet and lifestyle.

Knowing your number is empowering, not alarming. When you understand your Lp(a) level, you can work smarter on everything around it. Inflammation, atherogenic cholesterol, gut health, blood sugar, and nutrient adequacy are all modifiable. They all significantly shape your heart disease risk and trajectory.

Like the ApoB test, the Lp(a) lipoprotein lab test doesn’t require fasting before your blood draw.

Lp(a) levels: Lp(a) risk exists on a continuum, meaning the higher the level, the higher the cardiovascular risk. Levels below 75 nmol/L (30 mg/dL) are generally considered low risk, levels between 75 and 125 nmol/L (30-50 mg/dL) are considered intermediate risk, and levels at or above 125 nmol/L (50 mg/dL) are considered high risk. Levels closer to that 75 nmol/L threshold can shift during menopause, hormonal changes, or periods of inflammation, which is why more routine testing can be helpful for some people.

ApoB vs. Lipoprotein(a) Test: What’s the Difference?

Both tests measure cardiovascular risk that a standard lipid panel test misses, but they test different things. Here’s a breakdown:

ApoB test:

• Counts each atherogenic particle in your blood, including LDL, VLDL, IDL, and Lp(a)
• Tells you if you have more atherogenic lipoproteins carrying plaque-forming cholesterol that can deposit into the arterial wall
• Responds well to targeted, personalized science based nutrition, lifestyle, and medication changes

Lipoprotein(a) test:

• Measures Lp(a) specifically, since it behaves differently from other lipoproteins
• Reflects primarily genetic risk, not lifestyle-driven risk
• Signals the need to manage all other modifiable risk factors more aggressively

Used together, these two tests give you a significantly more complete picture of your true heart disease risk than LDL cholesterol alone. If you’re wondering what does ApoB measure versus what Lp(a) measures, the simplest answer is this: ApoB counts all atherogenic particles, while Lp(a) isolates one genetically driven risk enhancer that standard lipid testing misses entirely. 

Who Should Get ApoB Testing and Lipoprotein(a) Testing?

The short answer is most adults should get ApoB and Lp(a) tested. It’s now recommended that Lp(a) be measured at least once in adulthood for all adults. As a cardiology dietitian, I recommend checking it more often since there is some variance in levels. 

Despite elevated Lp(a) affecting as many as 1 in 5 people, only 1 in 300 adults have ever been tested.

ApoB testing is especially valuable when LDL cholesterol appears normal, but other risk factors are present. It directly counts atherogenic particles that standard cholesterol testing misses, making it particularly useful for people with diabetes, insulin resistance, or elevated triglycerides. People with high apolipoprotein B are at significantly higher risk for cardiovascular events. This is true even when their standard lipid panel looks normal, because ApoB is a better marker of risk than LDL alone.

Testing both markers is especially important if you have any of the following:

• A family history of early heart disease or heart attack
• Rising cholesterol during perimenopause or menopause
• Diabetes or insulin resistance
• Normal LDL but persistent cardiovascular concerns
• Known cardiovascular disease or a prior cardiac event

If your Lp(a) comes back elevated, your first-degree family members should be tested too, since it runs in families. Knowing this number allows us to adjust your lab targets. Since Lp(a) is a risk enhancer, that can help guide more aggressive risk reduction strategies to lower your heart attack risk. 

For those with elevated ApoB or Lp(a), imaging can provide additional insight into existing plaque burden. A coronary artery calcium (CAC) score measures calcified plaque in your coronary arteries. It helps determine how aggressively to manage your lipid targets. But a CAC score of zero is not always reassuring, especially in younger people, who are more likely to have soft, non-calcified plaque that CAC simply cannot detect.

For a more complete picture, your healthcare provider may also recommend a CCTA (coronary CT angiography), carotid ultrasound, or femoral ultrasound, which can identify plaque that CAC alone would miss.

Together, these tools give you the most complete picture of your heart disease risk. You can learn more about the full range of cardiac markers worth knowing in my Understanding Your Cardiac Panel Labs guide.

What Do Your ApoB Test Results Mean?

Your ApoB test results reflect the total number of atherogenic particles circulating in your blood. Because each atherogenic particle carries exactly one ApoB molecule, a higher ApoB number means more particles available to contribute to plaque formation. Understanding what is a good ApoB level for your individual risk profile is just as important as getting the test in the first place. The apolipoprotein B reference range below is a general guide, but your healthcare provider should always help interpret your specific results in context.

Here are general ApoB targets:

• General Popluation: Below 90 mg/dL
• Moderate Cardiovascular Risk: Below 80 mg/dL
• High Cardiovascular Risk: Below 60-70 mg/dL

Your ideal ApoB target should be determined with your healthcare provider or cardiology care team, since lower targets may be recommended depending on your overall risk profile. 

For Lp(a), here is what your numbers mean:

• Low risk: Below 75 nmol/L (30 mg/dL)
• Intermediate risk: 75 to 125 nmol/L (30 to 50 mg/dL)
• High risk: 125 nmol/L (50 mg/dL) or above 

These results need to be interpreted alongside other important markers including LDL cholesterol, HDL cholesterol, hs-CRP, triglycerides, blood sugar, and imaging when appropriate to provide a more complete picture of your cardiovascular health. 

Knowing your ApoB levels and Lp(a) gives you the information needed to take targeted, meaningful action. If you want to understand exactly what your results mean and what optimal targets look like for your individual risk profile, my Know Your Numbers: Heart Labs Explained course walks you through additional markers in plain language so you can advocate for your heart health with confidence.

How to Lower ApoB Levels

Unlike Lp(a), which is largely genetic, ApoB levels respond well to targeted nutrition and lifestyle changes. Every 10 mg/dL reduction in ApoB is associated with meaningful reductions in cardiovascular mortality and major cardiac events. That means the actions you take today directly move the needle on your risk.

Here’s what the evidence supports for treatment of high apolipoprotein B:

• Increase soluble fiber. Foods high in fiber like oats, legumes, ground flaxseed, and vegetables support a healthy gut microbiome helping regulate cholesterol metabolism and supporting long-term cardiovascular health. 
• Address insulin resistance. Excess blood sugar drives the liver to produce more VLDL particles, raising ApoB directly. Balancing carbohydrate intake, managing body weight, and staying active all help.
• Choose anti-inflammatory fats. Replacing saturated fats with omega-3 fatty acids and monounsaturated fats from sources like fatty fish, olive oil, and walnuts supports healthier lipid particle profiles.
• Close nutrient gaps. As Sandra’s case showed, even a whole food diet can fall short of meeting all nutrient needs, especially through menopause. A personalized, targeted plan that ensures nutrient adequacy supports both cholesterol metabolism and overall cardiovascular health.
• Medications when appropriate. Statins, PCSK9 inhibitors, and ezetimibe all reduce ApoB by clearing atherogenic particles from circulation. Your healthcare provider can determine whether medication is appropriate alongside nutrition and lifestyle changes. Diet is always an important piece of the puzzle, helping address inflammation, nutrient inadequacies, blood sugar regulation, gut health, and other factors that can accelterate heart disease progression. Learn more about heart disease treatment beyond old-school advice.

For elevated Lp(a), the focus shifts to managing all other modifiable risk factors more aggressively, particularly driving ApoB and LDL cholesterol to lower targets than standard guidelines would otherwise suggest.

FAQs

Is ApoB a good indicator of high cholesterol?

ApoB is actually a more precise indicator of cardiovascular risk than traditional cholesterol measurements. While LDL cholesterol measures the amount of cholesterol carried inside particles, the ApoB test directly counts every atherogenic particle in circulation. Someone can have a normal LDL cholesterol level but an elevated ApoB, indicating a higher number of plaque-forming particles. In these cases, ApoB is often a stronger predictor of cardiovascular disease risk than LDL cholesterol alone.

This is especially true in people with diabetes, insulin resistance, or elevated triglycerides, where LDL cholesterol can underestimates true cardiovascular risk.

Should everyone be tested for apolipoprotein B?

Most adults would benefit from apolipoprotein B testing, particularly those with diabetes, insulin resistance, metabolic syndrome, or a family history of heart disease. It’s especially valuable when LDL cholesterol appears normal but other cardiovascular risk factors are present. ApoB testing is also useful for tracking your progress, since it gives a more complete picture of whether your nutrition, lifestyle, and any medications are actually reducing your atherogenic particle burden, not just moving your cholesterol numbers.

Is the standard lipid panel test outdated and misleading?

A standard lipid panel doesn’t tell the full story of cardiovascular risk. Research shows that nearly 75% of patients hospitalized with coronary artery disease had LDL cholesterol in the normal range. Both non-HDL cholesterol and ApoB outperform LDL alone, but ApoB is the more accurate marker, especially in people with diabetes, obesity, metabolic syndrome, or elevated triglycerides.

When ApoB is not available, non-HDL cholesterol is the best alternative. The standard lipid panel also misses Lp(a) and inflammatory markers like hs-CRP, both of which independently drive plaque progression even when total cholesterol looks completely normal.

Should more doctors screen patients for lipoprotein(a)?

Yes, more doctors should screen patients for lipoprotein(a), and the evidence strongly supports it. Elevated Lp(a) affects 10 to 20% of the population, yet fewer than 1% of adults have ever been tested. Lp(a) is pro-atherosclerotic, pro-inflammatory, and pro-thrombotic, meaning it drives plaque buildup, fuels arterial inflammation, and promotes blood clot formation all at once. The 2026 ACC/AHA Dyslipidemia Guideline now recommends universal Lp(a) screening for all adults at least once in their lifetime. Knowing your number allows you to adjust lipid targets and manage your overall cardiovascular risk profile more proactively.

What are the risks of high lipoprotein(a) levels?

Elevated Lp(a) raises the risk of heart attack, stroke, aortic stenosis, and heart failure. Lp(a) also interferes with the body’s ability to break down blood clots, increasing thrombotic risk on top of its atherogenic effects. Lp(a) also carries oxidized phospholipids that drive inflammation directly within the artery wall, which means elevated Lp(a) compounds risk through multiple pathways simultaneously.

Research shows you have far more control than you might think. The EPIC-Norfolk study found that people with elevated Lp(a) who maintained a healthy lifestyle had a 67% lower risk of cardiovascular events compared to those with elevated Lp(a) and poor lifestyle habits. That is a profound difference driven entirely by modifiable factors. Since Lp(a) itself is largely genetic, the focus shifts to managing inflammation, science based targeted nutrition, ApoB, blood sugar, and gut health more aggressively and proactively.

For someone with a family history of heart disease but normal cholesterol, what tests should they consider?

Normal cholesterol does not equal low risk, especially with a family history of heart disease. Ask your healthcare provider about labs including an ApoB test, a lipoprotein(a) test, hs-CRP to assess arterial inflammation, and fasting glucose and insulin to rule out insulin resistance. Imaging such as a coronary artery calcium score, CCTA, carotid ultrasound, or femoral ultrasound can further evaluate existing plaque burden throughout the body. My Know Your Numbers: Heart Labs Explained course walks you through additional lab markers so you can advocate confidently for the right testing.

Meet the Author

Michelle Routhenstein is a Registered Dietitian Nutritionist, Preventive Cardiology Nutritionist, and Certified Diabetes Educator with over 14 years of experience specializing in cardiovascular nutrition. As the owner of Entirely Nourished, she takes a nutrient first, science based, and personalized approach to the prevention and management of heart disease.

Michelle has helped thousands of people address the underlying root causes of heart disease, improve heart function and heart failure, lower their blood pressure and cholesterol levels, and truly reduce their risk of heart attacks and strokes.

If you’re ready to take a personalized, science based approach to improving your heart health, book a complimentary discovery call to learn how targeted nutrition can support your heart health. Take the first step and book your complimentary discovery call here.

Want the foundations first? Consider starting with Optimize, her 6-week live group program, where you’ll build a strong foundation in science based heart health nutrition before diving deeper into personalized 1:1 work.

References

1. Devaraj, S., Semaan, J. R., & Jialal, I. (2023). Biochemistry, Apolipoprotein B. In StatPearls. StatPearls Publishing.
2. Farzam K, Zubair M, Senthilkumaran S. Lipoprotein A. [Updated 2024 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570621/
3. Rendler, J., Murphy, M., & Yeang, C. (2024). Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease. Health care. Current reviews, 12(2), 397.
4. Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021). Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites, 11(10), 690. https://doi.org/10.3390/metabo11100690
5. Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020). Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. European journal of preventive cardiology, 27(12), 1255–1268. https://doi.org/10.1177/2047487319871733
6. Langlois, M. R., & Sniderman, A. D. (2020). Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. Current cardiology reports, 22(8), 67. https://doi.org/10.1007/s11886-020-01323-z
7. Sachdeva, A., Cannon, C. P., Deedwania, P. C., Labresh, K. A., Smith, S. C., Jr, Dai, D., Hernandez, A., & Fonarow, G. C. (2009). Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. American heart journal, 157(1), 111–117.e2. https://doi.org/10.1016/j.ahj.2008.08.010
8. Di Fusco, S. A., Maggioni, A. P., Scicchitano, P., Zuin, M., D’Elia, E., & Colivicchi, F. (2023). Lipoprotein (a), Inflammation, and Atherosclerosis. Journal of clinical medicine, 12(7), 2529. https://doi.org/10.3390/jcm12072529
9. Perrot, N., Verbeek, R., Sandhu, M., Boekholdt, S. M., Hovingh, G. K., Wareham, N. J., Khaw, K. T., & Arsenault, B. J. (2017). Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis, 256, 47–52. https://doi.org/10.1016/j.atherosclerosis.2016.11.010
10. Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., Soffer, D. E., Taub, P. R., Wilkinson, M. J., Wilson, D. P., & Ballantyne, C. M. (2024). A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of clinical lipidology, 18(3), e308–e319. https://doi.org/10.1016/j.jacl.2024.03.001